158 filings
Page 3 of 8
8-K
l0zu bfui62
11 Aug 22
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
4:04pm
8-K
zrp3f5j83x4i
11 Jul 22
Results of Operations and Financial Condition
4:12pm
8-K
zd4553z6fp31cybuboq
27 Jun 22
Regulation FD Disclosure
4:25pm
8-K
8rnn8 iyjp3e1a79
16 Jun 22
Submission of Matters to a Vote of Security Holders
4:29pm
8-K
d5w96k
13 May 22
Departure of Directors or Certain Officers
4:56pm
8-K
t4x nj90l
12 May 22
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
4:08pm
8-K
4z7138 ms
3 May 22
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
4:08pm
DEFA14A
hzb liv7o
26 Apr 22
Additional proxy soliciting materials
4:32pm
S-8
mo6ln9u70v75udl
17 Mar 22
Registration of securities for employees
5:06pm
8-K
v9azflo41iwqmzzicjpa
17 Mar 22
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
4:05pm
8-K
wahplmdeuxq4z
7 Jan 22
Results of Operations and Financial Condition
5:00pm
8-K
61je 9kcabb
20 Dec 21
Termination of a Material Definitive Agreement
5:21pm
S-3ASR
f73 at1y7h
20 Dec 21
Automatic shelf registration
5:01pm
8-K
wsnf1dy0
10 Dec 21
Departure of Directors or Certain Officers
4:10pm
8-K
y7u8qu2oezrydyotzk27
19 Nov 21
Entry into a Material Definitive Agreement
6:08am
424B5
sqb9m8
19 Nov 21
Prospectus supplement for primary offering
6:05am